Disappointing study results for Cytokinetics

Cytokinetics Inc. (Nasdaq: CYTK) reported disappointing results from a Phase 3 clinical trial of tirasemtiv to treat patients with amyotrophic lateral sclerosis. Shares of the biopharmaceutical plunged $2.85 to close at $8.25.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.